Report

TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 13
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 DBMR TRIPOD DATA VALIDATION MODEL 20
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.6 MULTIVARIATE MODELLING 24
2.7 TYPE LIFELINE CURVE 24
2.8 MARKET APPLICATION COVERAGE GRID 25
2.9 DBMR MARKET POSITION GRID 26
2.10 VENDOR SHARE ANALYSIS 27
2.11 SECONDARY SOURCES 28
2.12 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
3.1 MERGERS AND ACQUISITION 32
3.2 PIPELINE ANALYSIS FOR GERMANY POST-TRAUMATIC STRESS DISORDER MARKET 33
3.2.1 RECENT APPROVALS 34
3.3 PESTEL ANALYSIS 35
3.4 PORTER'S FIVE FORCES MODEL 36
4 REGULATIONS OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 37
4.1 REGULATORY AND DRUG APPROVAL SCENARIO IN GERMANY 37
4.2 APPROVAL FRAMEWORK 37
4.2.1 CLINICAL PRACTICE 38
4.2.2 MARKETING AUTHORIZATION 38
5 INDUSTRY INSIGHTS 41
5.1 PATENT ANALYSIS 41
5.1.1 DRUG TREATMENT RATE BY MATURED MARKETS 41
5.1.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 41
5.1.3 KEY PRICING STRATEGIES 42
5.1.4 KEY PATIENT ENROLLMENT STRATEGIES 42
6 EPIDEMIOLOGY 43
6.1 HISTORIC PTSD POOL 43
6.2 PRESENT PTSD POOL 43
6.3 FURURE PTSD POOL 43
6.4 PREVALENCE OF DISSOCIATIVE PTSD BY COUNTRY 44
6.5 PREVALENCE OF UNCOMPLICATED PTSD BY COUNTRY 44
6.6 PREVALENCE OF COMORBID PTSD BY COUNTRY 44
6.7 TREATMENT RATE 45
7 INTRODUCTION 46
7.1 OVERVIEW 46
7.2 IMPACT OF UKRAINE AND RUSSIA WAR ON GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 46
7.3 IMPACT ANALYSIS ON DEMAND 46
7.4 CONCLUSION 47
8 MARKET OVERVIEW 48
8.1 DRIVERS 50
8.1.1 RISING PREVALENCE OF PTSD. 50
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF PTSD. 50
8.1.3 THE INCREASING INCIDENCE OF PTSD 50
8.1.4 INCREASED AWARENESS AMONG PATIENTS AND DOCTORS REGARDING THERAPIES FOR PTSD 51
8.2 RESTRAINTS 51
8.2.1 HIGH COST OF THE TREATMENT 51
8.2.2 SIDE EFFECTS ASSOCIATED WITH PTSD TREATMENT. 52
8.3 OPPORTUNITIES 52
8.3.1 RISING HEALTHCARE EXPENDITURE 52
8.3.2 RISING APPROVALS OF DRUGS 52
8.3.3 THE RISING NUMBER OF CLINICAL TRIALS IS EXPECTED TO BOOST THE GROWTH OF THE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET 53
8.4 CHALLENGES 53
8.4.1 PATENT EXPIRY OF DRUGS 53
8.4.2 RISING ALTERNATIVE THERAPIES 54
8.5 UNMEET NEEDS 54
8.5.1 UNMEET REIMBURSEMENT COST 54
8.5.2 MENTAL HEALTH STATUS AND SOCIAL CONDITIONS OF ASYLUM SEEKERS 55
9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE 56
9.1 OVERVIEW 57
9.2 UNCOMPLICATED PTSD 60
9.3 DISSOCIATIVE PTSD 60
9.4 COMORBID PTSD 60
9.5 OTHERS 61
10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT 62
10.1 OVERVIEW 63
10.2 PSYCHOTHERAPY 66
10.2.1 COGNITIVE BEHAVIORAL THERAPY 67
10.2.2 FAMILY THERAPY 67
10.2.3 STRESS INOCULATION THERAPY 67
10.2.4 PROLONGED EXPOSURE THERAPY 67
10.2.5 OTHERS 67
10.3 MEDICATION 67
10.3.1 ANTIDEPRESSANTS 68
10.3.1.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS 68
10.3.1.1.1 SERTRALINE 69
10.3.1.1.2 PAROXETINE 69
10.3.1.1.3 FLUOXETINE 69
10.3.1.1.4 CITALOPRAM 69
10.3.1.1.5 NEFAZODONE 69
10.3.1.1.6 OTHERS 69
10.3.1.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS 70
10.3.1.2.1 DULOXETINE 70
10.3.1.2.2 VENLAFAXINE 70
10.3.1.2.3 OTHERS 70
10.3.1.3 TRICYCLIC ANTIDEPRESSANTS 70
10.3.1.3.1 AMITRIPTYLINE 71
10.3.1.3.2 IMIPRAMINE 71
10.3.1.3.3 OTHERS 71
10.3.2 ANTIPSYCHOTICS 71
10.3.2.1 QUETIAPINE 72
10.3.2.2 ARIPIPRAZOLE 72
10.3.2.3 DIVALPROEX 72
10.3.2.4 LAMOTRIGINE 72
10.3.2.5 OTHERS 72
10.3.3 OTHERS 72
10.4 SOFTWARE DEVICES 72
10.4.1 PTSD COACH 73
10.4.2 PE COACH 73
10.4.3 CPT COACH 73
10.4.4 OTHERS 73
11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET , BY ROUTE OF ADMINISTRATION 74
11.1 OVERVIEW 75
11.2 ORAL 78
11.3 PARENTERAL 78
11.4 OTHERS 78
12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP 79
12.1 OVERVIEW 80
12.2 ADULTS 83
12.3 GERIATRICS 83
12.4 CHILDREN 84
13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 MENTAL HEALTH CENTERS 89
13.3 HOSPITALS 89
13.4 OUTPATIENT CLINICS 89
13.5 HOME HEALTHCARE 90
13.6 OTHERS 90
14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL 91
14.1 OVERVIEW 92
14.2 HOSPITAL PHARMACY 95
14.3 RETAIL PHARMACY 95
14.4 ONLINE PHARMACY 95
14.5 OTHERS 96
15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY LANDSCAPE 97
15.1 COMPANY SHARE ANALYSIS: GERMANY 97
16 SWOT ANALYSIS 98
17 COMPANY PROFILE 99
17.1 ABBVIE (2022) 99
17.1.1 COMPANY SNAPSHOT 99
17.1.2 REVENUE ANALYSIS 99
17.1.3 PRODUCT PORTFOLIO 100
17.1.4 RECENT DEVELOPMENT 100
17.2 VIATRIS INC. (2022) 101
17.2.1 COMPANY SNAPSHOT 101
17.2.2 REVENUE ANALYSIS 101
17.2.3 PRODUCT PORTFOLIO 102
17.3 PFIZER INC 103
17.3.1 COMPANY SNAPSHOT 103
17.3.2 REVENUE ANALYSIS 104
17.3.3 PRODUCT PORTFOLIO 104
17.3.4 RECENT DEVELOPMENTS 104
17.3.5 RECENT DEVELOPMENT 104
17.4 ELI LILLY AND COMPANY (2022) 105
17.4.1 COMPANY SNAPSHOT 105
17.4.2 REVENUE ANALYSIS 105
17.4.3 PRODUCT PORTFOLIO 106
17.4.4 RECENT DEVELOPMENT 106
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022) 107
17.5.1 COMPANY SNAPSHOT 107
17.5.2 REVENUE ANALYSIS 107
17.5.3 PRODUCT PORTFOLIO 108
17.5.4 RECENT DEVELOPMENT 108
17.6 ACCORD HEALTHCARE GMBH. 109
17.6.1 COMPANY SNAPSHOT 109
17.6.2 PRODUCT PORTFOLIO 109
17.6.3 RECENT DEVELOPMENTS 109
17.7 ALKERMES. 110
17.7.1 COMPANY SNAPSHOT 110
17.7.2 REVENUE ANALYSIS 110
17.7.3 PRODUCT PORTFOLIO 111
17.7.4 RECENT DEVELOPMENTS 111
17.8 ASTRAZENECA (2022) 112
17.8.1 COMPANY SNAPSHOT 112
17.8.2 REVENUE ANALYSIS 112
17.8.3 PRODUCT PORTFOLIO 113
17.8.4 RECENT DEVELOPMENT 113
17.9 AUROBINDO PHARMA. 114
17.9.1 COMPANY SNAPSHOT 114
17.9.2 REVENUE ANALYSIS 115
17.9.3 PRODUCT PORTFOLIO 115
17.9.4 RECENT DEVELOPMENTS 115
17.10 CIPLA INC. (2022) 116
17.10.1 COMPANY SNAPSHOT 116
17.10.2 REVENUE ANALYSIS 116
17.10.3 PRODUCT PORTFOLIO 117
17.10.4 RECENT DEVELOPMENT 117
17.11 DR. REDDY'S LABORATORIES LTD 118
17.11.1 COMPANY SNAPSHOT 118
17.11.2 REVENUE ANALYSIS 118
17.11.3 PRODUCT PORTFOLIO 119
17.11.4 RECENT DEVELOPMENTS 119
17.12 GLAXOSMITHKLINE GROUP OF COMPANIES. 120
17.12.1 COMPANY SNAPSHOT 120
17.12.2 REVENUE ANALYSIS 120
17.12.3 PRODUCT PORTFOLIO 121
17.12.4 RECENT DEVELOPMENTS 121
17.13 LUPIN (2022) 122
17.13.1 COMPANY SNAPSHOT 122
17.13.2 REVENUE ANALYSIS 122
17.13.3 PRODUCT PORTFOLIO 123
17.13.4 RECENT DEVELOPMENT 123
17.14 NOVARTIS AG 124
17.14.1 COMPANY SNAPSHOT 124
17.14.2 REVENUE ANALYSIS 124
17.14.3 PRODUCT PORTFOLIO 125
17.14.4 RECENT DEVELOPMENTS 125
17.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 126
17.15.1 COMPANY SNAPSHOT 126
17.15.2 REVENUE ANALYSIS 126
17.15.3 PRODUCT PORTFOLIO 127
17.15.4 RECENT DEVELOPMENTS 127
17.16 ZYDUS PHARMACEUTICALS, INC. (2022) 128
17.16.1 COMPANY SNAPSHOT 128
17.16.2 REVENUE ANALYSIS 128
17.16.3 PRODUCT PORTFOLIO 129
17.16.4 RECENT DEVELOPMENT 129
18 QUESTIONNAIRE 130
19 RELATED REPORTS 133